The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Risk of disease progression (PD) following discontinuation of BRAF±MEK targeted therapies for reasons other than PD in patients (pts) with metastatic or unresectable melanoma.
 
Francesca Corti
No Relationships to Disclose
 
Giovanni Randon
Travel, Accommodations, Expenses - Sanofi/Aventis
 
Marta Bini
No Relationships to Disclose
 
Alessandra Raimondi
No Relationships to Disclose
 
Sara Manglaviti
No Relationships to Disclose
 
Emma Zattarin
No Relationships to Disclose
 
Ilaria Bisogno
No Relationships to Disclose
 
Irene Vetrano
No Relationships to Disclose
 
Carolina Cimminiello
No Relationships to Disclose
 
Filippo G. De Braud
Honoraria - Bristol-Myers Squibb; Merck; MSD; Pfizer; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Bristol-Myers Squibb; EMD SERONO; Ignyta; Incyte; Nerviano Medical Sciences; Octimet; Pierre Fabre; Roche; Sanofi; Teofarma
Speakers' Bureau - Menarini
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Roche (Inst); SERVIER (Inst); Tesaro (Inst)
 
Michele Del Vecchio
No Relationships to Disclose
 
Lorenza Di Guardo
No Relationships to Disclose